Applicants' Specification

The specification includes the following Abstract as was filed with the application:

(Applicants respectfully note that there is/was an abstract filed with the application, per the PCT version as-published, as well as the US Publication Version. Even so, the following is from the PCT application, of which the current is a national phase under 35 U.S.C. 371)

Compounds of formula G_1-L-G_2, where -G_1 is a radical structurally close to cryptolepine, -L- is a single covalent bond or a covalent linking biradical selected from $(CH_2)_rNR'''(CH_2)_s$ and $-(CH_2)_rNR'''(CH_2)_SNR''''(CH_2)_t$-, -R''' and -R'''' are radicals, same or different, selected from the group consisting of H and (C_1-C_3)-alkyl; r , s and t are an integer from 1 to 3 and, -G_2 is H or a radical structurally close to -G_1, are intercalators. They are compounds which intercalate between DNA base pairs, and are useful as therapeutic agents against cancer, as assess by an in vitro test of cytotoxicity with human leukemia cells Jurkat E6-1 and human carcinoma cells GLC-4. Preferred compounds are those where -G_1 is bonded to -L- through a carbonyl amino and -L-is -$(CH_2)_3NCH_3(CH_2)_3$ or $-(CH_2)_2NCH_3(CH_2)_SNCH_3(CH_2)_2$- where s = 2 or 3. -$G_1$ is a radical selected from (IIa) y (IIb); -G_2 is a radical selected from H, a radical of formula (IIa), a radical of formula (IIb), the N-radical of 1,8-naphthalimide, the C4-radical of 2-phenylquinoline, and the C9-radical of acridine.